Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

Imagem de Miniatura
Arquivos
art_BUTLER_Effects_of_Empagliflozin_in_Women_and_Men_With_2022.PDF (1.01 MB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
BUTLER, Javed
FILIPPATOS, Gerasimos
SIDDIQI, Tariq Jamal
FERREIRA, Joao Pedro
BRUECKMANN, Martina
BOHM, Michael
CHOPRA, Vijay K.
GIANNETTI, Nadia
IWATA, Tomoko
Citação
CIRCULATION, v.146, n.14, p.1046-1055, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). Methods: The effects of empagliflozin on the primary outcome of cardiovascular death or hospitalization for HF and on secondary outcomes (including total HF hospitalization, cardiovascular and all-cause mortality, and Kansas City Cardiomyopathy Questionnaire scores) were compared in women and men in the overall cohort and in subgroups defined by left ventricular ejection fraction (41%-49%, 50%-59%, and & GE;60%). The effects of empagliflozin on physiological measures, including changes in systolic blood pressure, uric acid, hemoglobin, body weight, and natriuretic peptide levels, were also assessed. Results: Of the 5988 patients randomized, 2676 (44.7%) were women. In the placebo arm, women tended to have lower risk for adverse outcomes, including a lower risk of all-cause mortality (hazard ratio, 0.69 [95% CI, 0.56, 0.84]). Compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for HF to a similar degree in both sexes (hazard ratio, 0.81 [95% CI, 0.69, 0.96] for men; and hazard ratio, 0.75 [95% CI, 0.61, 0.92] for women; P-interaction=0.54). Sex did not modify the relationship between empagliflozin and outcomes across ejection fraction groups. Similar results were seen for secondary outcomes and physiological measures. Compared with placebo, empagliflozin improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score to a similar extent in both sexes (1.38 for men versus 1.63 for women at 52 weeks; P-interaction=0.77); the results were similar for Kansas City Cardiomyopathy Questionnaire overall summary score and total summary score. Conclusions: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction.
Palavras-chave
empagliflozin, health status, heart failure, hospitalization, men, women
URI
https://observatorio.fm.usp.br/handle/OPI/50467
Referências
  1. Anker SD, 2019, EUR J HEART FAIL, V21, P1279, DOI 10.1002/ejhf.1596
  2. Beale AL, 2019, JACC-HEART FAIL, V7, P239, DOI 10.1016/j.jchf.2019.01.004
  3. Boehringer Ingelheim, DAT DOC SHAR
  4. Borlaug BA, 2011, CIRCULATION, V123, P2006, DOI 10.1161/CIRCULATIONAHA.110.954388
  5. Butler J, 2022, EUR HEART J, V43, P416, DOI 10.1093/eurheartj/ehab798
  6. Center for Global Clinical Research Data, VIVL
  7. Cleland JGF, 2006, EUR HEART J, V27, P2338, DOI 10.1093/eurheartj/ehl250
  8. Dewan P, 2020, EUR J HEART FAIL, V22, P898, DOI 10.1002/ejhf.1776
  9. Gori M, 2014, EUR J HEART FAIL, V16, P535, DOI 10.1002/ejhf.67
  10. Lam CSP, 2012, CIRC-HEART FAIL, V5, P571, DOI 10.1161/CIRCHEARTFAILURE.112.970061
  11. McMurray JJV, 2020, CIRCULATION, V141, P338, DOI 10.1161/CIRCULATIONAHA.119.044491
  12. Merrill M, 2019, JACC-HEART FAIL, V7, P228, DOI 10.1016/j.jchf.2019.01.003
  13. O'Meara E, 2007, CIRCULATION, V115, P3111, DOI 10.1161/CIRCULATIONAHA.106.673442
  14. Packer M, 2020, EUR J HEART FAIL, V22, P1551, DOI 10.1002/ejhf.1902
  15. Santos-Gallego CG, 2021, J AM COLL CARDIOL, V77, P243, DOI 10.1016/j.jacc.2020.11.008
  16. Scantlebury DC, 2011, CURR OPIN CARDIOL, V26, P562, DOI 10.1097/HCO.0b013e32834b7faf
  17. Stolfo D, 2019, JACC-HEART FAIL, V7, P505, DOI 10.1016/j.jchf.2019.03.011
  18. Young JB, 2004, CIRCULATION, V110, P2618, DOI 10.1161/01.CIR.0000146819.43235.A9

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03